Trial intelligence / Profile preview

AA4500 for Dupuytren's contracture

ACTRN12607000216415Phase 3Not yet recruiting

Sponsor
Auxilium Pharmaceuticals, Inc.
Start
Jul 2007
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Countries
1
01

Overview

Phase 3, randomised, double-blind trial of collagenase clostridium histolyticum in Dupuytren's contracture (3 arms), sponsored by Auxilium Pharmaceuticals, Inc. Primary endpoints: Safety by adverse events, vital signs, and grip strength, Safety by clinical laboratory tests and 2 more. Planned start Jul 2007; status: not yet recruiting.

02

Drugs

collagenase clostridium histolyticum
03

Conditions

Dupuytren's contracture

Beyond the preview

Go deeper on ACTRN12607000216415.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12607000216415.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call